Aizon, a San Francisco, CA-based Artificial Intelligence (AI) SaaS AI-enhanced pharmaceutical manufacturing company, raised $20M in Series C funding.
The round was led by NewVale Capital with participation from existing investors Atlantic Bridge, Crosslink Capital, and Uncork Capital.
The company intends to use the funds to accelerate its development pipeline, and better serve its customers.
Led by CEO Pep Gubau, Aizon leverages advanced predictive analytics, artificial intelligence, and other smart factory technologies to provide an accessible GMP AI platform for pharmaceutical manufacturers. With Aizon, customers can access to insights and enhanced decision-making capabilities and can discover new optimisation paths, reduce costs, predict deviations, and enhance their manufacturing systems. The system prioritises rigorous quality and compliance and follows GAMP5 for GMP processes to ensure compliant data acquisition, storage, and consumption.
FinSMEs
08/02/2024